Ken Griffin’s Aligos Therapeutics ALGS Stock Holding History

Ken Griffin’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-12	Closed	-$105	–	14162
2024 Q2	$105	Buy	12 +4	+50%	+$70	﹤0.01%	14095
2024 Q1	$196	Buy	+8	New	+$159	﹤0.01%	14397
2023 Q2	–	Sell	-4	Closed	-$87	–	14271
2023 Q1	$87	Hold	4	–	–	﹤0.01%	14593
2022 Q4	$95	Buy	+4	New	+$101	﹤0.01%	14764
2022 Q2	–	Sell	-640	Closed	-$34K	–	12790
2022 Q1	$34K	Buy	+640	New	+$51.3K	﹤0.01%	13032

Other funds holding ALGS

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ken Griffin's ALGS Position: Q1 2026 in Review

Ken Griffin increased its Aligos Therapeutics (ALGS) stake by 4.8% in Q1 2026, buying an estimated $18.8K and bringing the position to 54,311 shares worth $404K. The position accounts for ﹤0.01% of the portfolio, ranked #9800.

Ken Griffin first reported a position in ALGS in Q2 2021 and has held it in 14 quarters since. The position peaked at $483K in Q4 2025. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

Ken Griffin held 54,311 shares of Aligos Therapeutics worth $404K as of Q1 2026.
Ken Griffin bought 2,477 Aligos Therapeutics shares in Q1 2026, an estimated $18.8K.
Aligos Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #9800 holding.
Ken Griffin first reported a position in Aligos Therapeutics in Q2 2021 and has held it in 14 quarters since.
Ken Griffin's Aligos Therapeutics position peaked at $483K in Q4 2025.
35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.